GraceFinance · Source-backed public company research
InflaRx N.V. (IFRX)
Nasdaq · Manufacturing · Pharmaceutical Preparations
Core research established · 4/4 core data layers currently established
What InflaRx N.V. does
A. History and development of the company We are a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, an inherent part of the innate immune system. We discover, develop and commercialize first-in-class, highly potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With our therapeutic product candidates in clinical development, vilobelimab and izicopan (formerly known as INF904), we target C5a and its receptor C5aR to selectively to inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. We discovered and developed both products candidates through our own internal efforts. Our legal and commercial name is InflaRx N.V.
Open the company story
The live GraceFinance page shows source-backed financial changes, management context, guidance, confirmed events, risks, and connected history only when the applicable evidence and relationships have been established. Missing research stays visible instead of being inferred.